

Management

Stephen Collins, MD, PhD
President & Chief Executive Officer

Michael Venuti, PhD
Chief Scientific Officer

Holli Carlson
Vice President, Operations

Todd Verdoorn, PhD
Vice President, Neurobiology

Stephen Wanaski, PhD
Vice President, Research & Development

Brian Williams
Vice President, Corporate Development & Finance

Board of Directors

Thomas Beck, MD
Fidelity Biosciences

Jason Brown, PhD
Thomas McErney & Partners

Stephen Collins, MD, PhD
President & Chief Executive Officer

Rajeev Dadoo, PhD
SR One

Luke Evin, PhD
MPM Capital

Corey Goodman, PhD
Independent Director

Elaine Jones, PhD
Pfizer Ventures

Heath Lukatch, PhD
Novo Ventures

Overview

NeuroTherapeutics Pharma, Inc. (NTP) is a biopharmaceutical company developing new therapies to treat pain, epilepsy, and other nervous system disorders. NTP is advancing compounds that act through a novel mechanism of action to create a new class of medicines with potential broad application across a range of neurological and neuropsychiatric conditions.

Adequate and safe control of pain and epilepsy represent significant unmet medical needs today. While currently available medications in these areas provide some benefit for some patients, much of the patient population with pain, epilepsy and related conditions contend with a combination of inadequate symptom relief and significant side effects caused by their treatment.

NTP is developing first-in-class therapeutics with the potential to change the standard of care for these patients. NTP's novel compounds act through a previously unexplored mechanism of action unlike those of existing therapies. This approach has the potential to provide patients with a new way to treat neurological disorders and a way to improve upon both efficacy and safety.

Technology

NeuroTherapeutics Pharma has identified drug candidates that act through a new mechanism of action, modulating a novel therapeutic target within a well-validated inhibitory neuronal pathway. These molecules modulate a specific subset of GABA_A receptors while having no activity at classic, post-synaptic GABA receptors.

Further, they preferentially enhance inhibition at times of abnormal neuronal excitability. By acting during such states, and only in specific regions of the brain, NTP compounds have repeatedly shown significant efficacy in a range of *in vivo* models of disease pathology, coupled with a consistent lack of the sedative and cognitive side effects which are typically observed with classic GABAergic drug mechanisms.

Extensive molecular pharmacology studies have demonstrated both selectivity for specific GABA_A receptors, which are up-regulated in disease states, as well as preferential activity at times when receptor function is aberrant. These effects seen at the target are consistent with data that demonstrate increased inhibitory drive in hippocampal brain slice models of epilepsy and spinal cord preparations from animals with neuropathic pain conditions. NTP drug candidates demonstrated a wide breadth of activity across animal models of neurological disorders including epilepsy, neuropathic, inflammatory and acute pain, anxiety, and migraine. This mechanism may also provide therapeutic potential in other psychiatric disorders.

Leadership

NTP is led by a management team with significant drug development experience and is financially backed by a well respected group of venture capital investors. The company raised a \$43 million Series B financing in May of 2010.